Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Martijn Akse"'
Autor:
Hannah Park, Diederick Keizer, Martijn van Zelst, Eveline den Biezen, Dianne Arnoldina Margaretha Wilhelmina Van Strijp, Saskia Vermeer, Anthony Magliocco, Martijn Akse
Publikováno v:
Cancer Research. 81:740-740
Introduction: OncoSignal test was developed to determine and quantify functional signal transduction pathway activity levels of 4 key oncogenic signaling pathways (ER, AR, PI3K and MAPK), based on the quantitative measurement of mRNA expression level
Autor:
Yvonne Wesseling-Rozendaal, Martijn Akse, Márcia Alves De Inda, A. van Brussel, H. van Ooijen, E. den Biezen-Timmermans, Wim Verhaegh, H. van Zon, Anke Pierik
Publikováno v:
European Journal of Cancer. 138:S88-S89
Autor:
Fabien Calvo, Patricia Martin-Romano, D. van Strijp, E. den Biezen-Timmermans, Maud Ngo-Camus, A. van de Stolpe, Claudio Nicotra, S. Vermeer-van de Laar, Martijn Akse, Sigi Neerken, Antoine Italiano
Publikováno v:
Annals of Oncology. 31:S791
Autor:
Alexander M.M. Eggermont, Fabien Calvo, Claudio Nicotra, Sieglinde Neerken, Martijn Akse, Christophe Massard, Eveline Den Biezen-Timmerman, Maud Ngo, Paul van de Wiel, Anja van de Stolpe, Patricia Martin-Romano
Publikováno v:
Cancer Research. 80:1331-1331
Introduction: Precision medicine has shown to improve outcomes of cancer patients by identifying oncogenic alterations and actionable mutations. Yet, most tests perform DNA sequencing and are not able to discriminate which tumor driving signaling pat
Autor:
Wim Verhaegh, Martijn Akse, Laurent Holtzer, Anne van Brussel, Eveline den Biezen-Timmermans, Yvonne Wesseling-Rozendaal, Márcia Alves De Inda, Henk van Ooijen, Sandra M. van den Bosch, Anke Pierik, Hans Van Zon
Publikováno v:
Cancer Research. 80:4261-4261
Introduction: Currently, the selection of targeted therapy is commonly based on genetic data, such as well-known gene mutations, but these mutations do not provide conclusive evidence for the functional activation of the affected pathway. For this re
Autor:
Martijn Akse, Eveline den Biezen-Timmermans, Jean-Yves Blay, Anja van de Stolpe, Nicolas Penel
Publikováno v:
Journal of Clinical Oncology. 38:e23558-e23558
e23558 Background: DF are locally invasive soft tissue tumors of fibroblast origin, with unpredictable course. CTTNB1 mutations are a hallmark of DF. Molecular-targeted therapies are lacking. Recently developed OncoSignal (www.philips.com/oncosignal)
Autor:
Patricia Martin, Maud Ngo-Camus, Claudio Nicotra, Fabien Calvo, Alexander M.M. Eggermont, Martijn Akse, Christophe Massard, Eveline den Biezen-Timmermans, Sigi Neerken, Anja van de Stolpe, Paul van de Wiel
Publikováno v:
Journal of Clinical Oncology. 38:e15606-e15606
e15606 Background: Precision medicine refers to tailoring of treatment to each individual patient, although identifying tumor driving signaling pathways (SP) that are functionally active is still a challenge. OncoSignal pathway tests quantitatively m
Autor:
Anu Fernando, A. van de Stolpe, Márcia Alves De Inda, Diederick Keizer, J.M. Dixon, Arran K Turnbull, Martijn Akse, Carlos Martinez-Perez, Andrew H. Sims, H. van Zon, Danielle Elisa Willemine Clout
Publikováno v:
Annals of Oncology. 30:v95
Background Despite ER positive IHC staining, some patients do not respond to neoadjuvant endocrine therapy, suggesting that ER staining lacks specificity to predict response. We developed a method to infer a quantitative signal transduction pathway a